Primary Squamous Cell Carcinoma of the Breast With 18 F-FDG PET/CT.

A 67-year-old woman presented with a palpable breast mass. A biopsy was taken, and the diagnosis was squamous cell carcinoma. Primary squamous cell carcinoma of breast is an extremely rare subtype of invasive breast cancer.

The Contribution of 68 Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer.

Aim: This study aimed to compare the diagnostic capabilities of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT imaging in staging gastric carcinoma, exploring the impact of 68 Ga-FAPI-04 PET/CT on treatment planning and its prognostic significance.

Methods: The research included 31 patients undergoing staging for gastric cancer, who received both 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT scans. We compared the SUV max and SUV mean of the primary tumor and lymph nodes, the count of organ metastases, tumor-to-background ratios, and overall staging accuracy.

Dual 177 Lu-Prostate-Specific Membrane Antigen and 177 Lu-DOTATATE Therapy in Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation.

We present an 87-year-old man diagnosed with prostate cancer and neuroendocrine differentiation, posttherapy results to consecutive 177 Lu-prostate-specific membrane antigen and 177 Lu-DOTATATE. Despite hormonal therapy and chemoradiotherapy, the patient progressed rapidly, and multiple liver and bone metastases showed regression after 177 Lu-prostate-specific membrane antigen and 177 Lu-DOTATATE treatment. Prostate cancer with neuroendocrine differentiation is resistant to treatments; however, treatment with the combination of 177 Lu-DOTATATE therapy may be promising.

Contribution of 68 Ga-DOTA-FAPI-04 PET/CT to Prostate Cancer Imaging : Complementary Role in PSMA-Negative Cases.

Purpose: Prostate-specific membrane antigen (PSMA)-targeted PET/CT is a well-established imaging method in prostate cancer (PC) for both staging and restaging, and also for theranostic applications. An alternative imaging method is crucial for 15% PSMA-negative cases. We aimed to investigate the contribution of 68 Ga-DOTA-FAPI-04 PET/CT to PC imaging.

Pneumonia with Intense Ga-FAPI Uptake Mimicking Metastasis on Ga-FAPI PET/CT in a Patient with Rectal Cancer.

A 70-year-old man with newly diagnosed rectum adenocarcinoma was referred to F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) for staging, and Ga-fibroblast activation protein inhibitor (FAPI)-04 PET/CT for ongoing trial. Both F-FDG PET/CT and Ga-FAPI-04 PET/CT showed intense uptake in the primary rectal tumor, and also in nodular areas in the right lung. Due to intense Ga-FAPI-04 and F-FDG uptake, the lung lesions were considered as metastases.

The potential role of 68Ga-FAPI-04 PET/CT for screening malignancy in suspected colonic lesions.

Aim: Benign colonic lesions like tubular adenoma may show intense uptake on F-18-FDG PET/CT and can be mistaken for malignancy. In this study, we evaluated the role of 68Ga-FAPI-04 PET/CT for discriminating the benign and malignant colonic lesions.

Methods: Forty patients with diagnosis of colorectal cancer who had undergone 18F-FDG-PET/CT and 68Ga-FAPI-04 PET/CT for initial staging were retrospectively analyzed.

68 Ga-FAPI-04 PET/CT in Selected Breast Cancer Patients With Low FDG Affinity : A Head-to-Head Comparative Study.

Purpose: In this prospective study, PET findings of 18 F-FDG PET/CT in breast cancer staging were compared with 68 Ga-FAP inhibitor (FAPI) 04 PET/CT findings in selected cases with relatively low 18 F-FDG uptake in the primary tumor or with suspected nodal or distant metastases.

Patients And Methods: Twenty-four women with a median age of 45 years (range, 36-67 years) who underwent initial staging 18 F-FDG PET/CT for breast cancer underwent 68 Ga-FAPI-04 PET/CT imaging within the same week. SUV max and quantities of primary tumors and locoregional and distant metastatic lesions were recorded from both images, and these data were compared statistically.

Testicular Metastasis of Jejunal Neuroendocrine Tumor on Ga-DOTATATE PET/CT.

Neuroendocrine tumors are slow-growing tumors originating from neuroendocrine cells and capable of metastasis. Most of them are found in the gastrointestinal tract; however, they can also be rarely seen in other organs. Testicular neuroendocrine tumors account for less than 1% of all testicular neoplasms.

Ga-FAPI-04 PET/CT Findings in Patients with Liver Cirrhosis.

Fibroblast activation protein (FAP) is expressed as a pro-inflammatory agent from fibrous tissue in liver cirrhosis and in the tumor microenvironment. Cirrhosis is the last stage of any chronic liver disease, and the natural course of cirrhosis is the progression from the asymptomatic phase to the symptomatic decompensated phase with the development of ascites. Although various clinical features suggest cirrhosis in patients with chronic liver disease, non-invasive methods should follow the clinical approach before a definitive diagnosis.

Findings of I-131 SPECT/CT, F-FDG, and Ga-FAPI-04 PET/CT Imaging in a Patient Treated with Radioiodine Therapy for Metastatic Papillary Thyroid Carcinoma.

A 50-year-old man undergone total thyroidectomy and histopathology revealed papillary thyroid carcinoma with a tumor size of 4.5 cm. The patient was referred to a nuclear medicine clinic for radioiodine therapy.

The roles of 68 Ga-PSMA PET/CT and 18 F-FDG PET/CT imaging in patients with triple-negative breast cancer and the association of tissue PSMA and claudin 1, 4, and 7 levels with PET findings.

Aim: Aim of study is to compare the results of Gallium-68-prostate-specific membrane antigen ( 68 Ga-PSMA) and 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography(PET)/computed tomography (CT), to evaluate the correlation between PET findings and the level of PSMA, Claudin (Clau) 1, 4, and 7 receptors obtained by immunohistochemical (IHC) analysis, and to determine potential predictive and prognostic values in TNBC.

Methods: Forty-seven lesions of 42 subjects diagnosed TNBC both underwent PET/CT scan for preoperative staging/restaging were prospectively included study. PSMA, Clau 1, 4, and 7 expressions were IHC evaluated from the biopsy samples of the primary tumor (PT).

Increased FDG Uptake in Skin Rashes Caused by EGFR Inhibitors.

Most patients treated with epidermal growth factor receptor inhibitors develop cutaneous advance effects. The extent and severity of treatment-related skin rashes are associated with good treatment response and prognosis. Herein, we presented increased uptake of the 18F-FDG in skin rashes after treatment with epidermal growth factor receptor inhibitors in 2 patients diagnosed with metastatic colorectal cancer.

Mild Ga PSMA-11 Uptake in Incidental Pituitary Adenoma.

A 76-year-old man with metastatic prostate cancer was referred to Ga prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) for restaging. A consecutive F-fluorodeoxyglucose (FDG) PET/CT was performed due to the history of lung cancer in the left lung treated with stereotactic radiotherapy. Intense F-FDG uptake was detected in the pituitary gland despite the mild uptake of Ga PSMA.

Chronic Gastritis Mimicking Malignancy on 68 Ga-FAPI-04 PET/CT.

We present 2 patients mimicking malignancy with intense gastric 68 Ga-FAPI-04 uptake on PET/CT. Both patients showed low to moderate 18 F-FDG uptake. Histopathology revealed chronic active gastritis.

Role of 68 Ga-FAPI PET/CT in Screening Malignancy of Familial Adenomatous Polyposis.

A 57-year-old man with familial adenomatous polyposis (FAP) and newly diagnosed colonic adenocarcinoma was referred to 18 F-FDG PET/CT for staging and 68 Ga-FAPI-04 PET/CT for ongoing trial. 18 F-FDG PET/CT showed equal intense 18 F-FDG uptake in the tumor and multiple hypermetabolic polypoid lesions in the entire colorectum. 68 Ga-FAPI-04 PET/CT showed intense 68 Ga-FAPI-04 uptake only at the colonic tumor, without uptake at polypoid lesions.

Late-Term Findings of Pancreatitis on 68 Ga-PSMA PET/CT in a Patient With Prostate Cancer.

The 68 Ga-PSMA PET/CT imaging modality is used to evaluate biochemical recurrence, response to treatment, and staging in prostate cancer. Prostate-specific membrane antigen (PSMA) receptor activation can be seen in benign and malignant diseases as well as in many physiological tissues. Many pitfalls and artifacts have been reported when reporting 68 Ga-PSMA PET/CT.

Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.

Herein, we present the results of 18F-FDG PET/CT and 68Ga-FAPI-4 PET/CT of a patient with metastatic Kaposi sarcoma. A 47-year-old man with suspected gastric cancer was referred to 18F-FDG PET/CT for diagnosis and staging. PET/CT detected increased 18F-FDG uptake in metastatic lymphadenopathies and liver lesions.

Two Cases of Acrometastasis from Lung Cancer Revealed on F-FDG PET/CT.

We present 2 cases of acrometastases that manifest as the first signs of underlying lung cancer. The first case is 37 year-old-man misdiagnosed and treated as having a traumatic fracture at the left thumb. The second case is a 77 year-old-man who received treatment for soft tissue infection at left hand for 4 weeks.

Multiple Subcutaneous F-FDG-avid Granulomas Due to Enoxaparin Injection.

A 67-year-old female patient with metastatic gastric adenocarcinoma was referred to fluorine-fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) for restaging. PET/CT revealed liver metastasis and the patient received six-cycles of chemotherapy. On control F-FDG PET/CT the liver lesion disappeared but newly formed multiple foci of increased uptake in the subcutaneous adipose tissues of the abdominal wall were detected.

Diagnostic impact of F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy.

Introduction: Immunotherapy is an effective treatment method for cancer cells with humoral and cellular immune mechanisms of action but triggers an inflammatory response and disrupts standard protective immune tolerance. Early detection of immune-related adverse events (irAEs) on PET/CT is crucial for patient management and subsequent therapy decisions. In this study, we aimed to evaluate the impact of F-FDG PET/CT on detecting of irAEs in patients receiving immunotherapy.

Gallbladder Metastasis From Renal Cell Carcinoma Revealed With 18 F-FDG PET/CT.

Gallbladder metastasis from renal cell carcinoma is a rare condition. To our knowledge, only 1 case has been reported with 18 F-FDG PET/CT findings. Herein, we report the case of a 53-year-old man with renal cell carcinoma, having gallbladder metastasis revealed with restaging 18 F-FDG PET/CT.

Intense 68 Ga-PSMA Uptake in Neurofibroma Mimicking Cutaneous Metastases in a Patient With Prostate Cancer.

Prostate cancer is the most common cancer in men. 68 Ga-PSMA PET/CT is frequently used in staging and restaging prostate cancer; it is important to keep in mind the causes of false-positives when evaluating imaging. We present findings of 68 Ga-PSMA PET/CT and histopathological features of a 68-year-old prostate cancer man with neurofibroma.

68 Ga-DOTATATE Uptake in Well-Differentiated Neuroendocrine Tumor of the External Auditory Canal.

A 38-year-old woman presented with a 4-month history of left-sided otalgia and otorrhea. Otoscopy revealed a mass in the left external auditory canal causing obliteration. A biopsy was taken, and the diagnosis was consistent with a well-differentiated neuroendocrine tumor.

Vas Deferens and Inguinal Canal Metastasis of Prostate Cancer Revealed by 68 Ga-Prostate-Specific Membrane Antigen PET/CT.

A 71-year-old man with prostate adenocarcinoma underwent 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT for staging. 68 Ga-PSMA PET/CT showed the primary lesion along with bladder, rectum, bilateral seminal vesicle invasion, and metastatic pelvic lymph nodes with intense 68 Ga-PSMA uptake. Also, PET/CT showed rarely seen bilateral vas deferens invasion and metastasis to the inguinal canal.